Objective-The tight regulation of platelet adhesiveness, mediated by the αIIbβ3 integrin, is critical for hemostasis and prevention of thrombosis. We recently demonstrated that integrin affinity in platelets is controlled by the guanine nucleotide exchange factor, CalDAG-GEFI (CD-GEFI), and its target, RAP1. In this study, we investigated whether lowlevel expression of CD-GEFI leads to protection from thrombosis without pathological bleeding in mice. Approach and Results-Cdg1 low mice were generated by knockin of human CD-GEFI cDNA into the mouse Cdg1 locus.
P latelet aggregate formation, mediated by activated integrin αIIbβ3, is critical for hemostasis on tissue injury. Excessive platelet activation and aggregation, however, can lead to thrombotic complications, such as heart attack and stroke. 1, 2 The signaling events required for platelet integrin activation are initiated by engagement of surface-expressed receptors for agonists, such as thrombin and collagen. 3 These agonists trigger a first wave of platelet signaling that includes a rapid increase in the cytosolic calcium concentration ([Ca 2+ ]i). This increase in [Ca 2+ ]i leads to activation of the calcium-binding guanine nucleotide exchange factor, CalDAG-GEFI (CD-GEFI; RASGRP2), a key regulator of the small GTPase RAP1. 4 RAP1 controls various platelet responses important for hemostatic plug formation, including the inside-out activation of integrin receptors. 5, 6 In the absence of additional signals, CD-GEFI-mediated RAP1 signaling is terminated by the GTPase-activating protein, RASA3. 7 The signal for RASA3 inactivation and sustained RAP1 signaling is provided by stimulation via P2Y12, the receptor for the second-wave mediator adenosine diphosphate and the target for various clinically used antiplatelet drugs. 8, 9 Work by us and others provided important mechanistic information on how interference with RAP1 signaling affects platelet adhesion at sites of vascular injury. Mice deficient in the main RAP1 isoform, RAP1B, exhibit marked defects in platelet aggregation to various agonists in vitro and impaired hemostasis and thrombosis in vivo. 10, 11 As outlined earlier, the activity state of RAP1 in platelets is controlled by CD-GEFI and RASA3. 4, 7 Active RASA3 is required to keep circulating platelets in a quiescent state. 7 During hemostatic plug formation, its activity must be down-modulated as part of the P2Y12/PI3 kinase signaling pathway in order for stable platelet adhesion to occur. Consistently, mice lacking RASA3 are characterized by severe thrombocytopenia because of platelet preactivation and clearance, 7 whereas both hemostatic plugs and pathological thrombi in mice lacking P2Y12 function are highly unstable. 9, 12 In contrast, RAP1 activation in platelets from mice lacking CD-GEFI occurs with a delay and requires higher doses of strong agonists, such as thrombin and collagen. Under flow conditions in vitro, platelets lacking CD-GEFI (Cdg1 −/− ) are markedly impaired in their ability to form 3-dimensional thrombi, especially under conditions of high shear stress. 12 Consistent with the in vitro phenotype, Cdg1 −/− mice are strongly protected from both immune-mediated thrombocytopenia and thrombosis and arterial thrombosis, but they also show a marked defect in hemostatic plug formation. 12, 13 Importantly, the main findings in Cdg1 −/− mice were recently confirmed in 3 patients with a loss-of-function mutation in CD-GEFI. In their studies, Canault et al found that platelets from heterozygous patients, who did not show defects in hemostasis, exhibited a significant adhesive defect under flow conditions. 14 Thus, the various studies in knockout mice and patients suggest partial inhibition of CD-GEFI as a powerful yet safe strategy to prevent thrombosis. In the present study, we describe a hypomorphic mouse strain expressing low levels of human CD-GEFI (Cdg1 low ) instead of the endogenous mouse CD-GEFI. Platelets from Cdg1 low mice showed decreased platelet activation when compared with wild-type (WT) controls. Importantly, however, their integrin activation response was significantly stronger than that of Cdg1 −/− mice. Consistent with the in vitro integrin activation phenotype, Cdg1 low mice exhibited only a mild defect in primary hemostasis, while they were strongly protected from experimental thrombosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Generation of Hypomorphic Cdg1 Mutant Mice
The platelet and hemostasis phenotype of Cdg1 −/− mice has been characterized extensively. To investigate the regulation of CD-GEFI function in platelets by genetic means, we aimed to establish a cDNA knockin model where WT or mutant human Cdg1 cDNA is knocked into the murine Cdg1 locus ( Figure 1 ). We selected to express human CD-GEFI variants in mice because (1) there is 96% and 100% amino acid sequence identity between human and murine CD-GEFI and RAP1B, respectively, and (2) this approach would allow us to evaluate the ability of human CD-GEFI variants to support platelet activation and plug formation in mice. We noticed, however, that the cDNA knockin of human Cdg1 led to markedly reduced expression of CD-GEFI protein in platelets isolated from these mice (≈90% reduction compared with controls; Figure 2A ), whereas the expression of RASA3, RAP1, or β-ACTIN was not affected. Just like Cdg1 −/− mice, 4 these Cdg1 low mice exhibited a small but significant increase in circulating neutrophils, but they did not exhibit changes in the peripheral platelet count or the platelet size (Table) . However, compared with WT controls, platelets from Cdg1 low mice showed marked defects in RAP1 activation in response to agonist stimulation ( Figure 2B ). Thus, cDNA knockin of human Cdg1 strongly reduced platelet CD-GEFI expression and, thus, led to the generation of hypomorphic Cdg1 mutant mice.
Impaired Integrin Activation and Aggregation of Cdg1 low Platelets
Consistent with the defect in RAP1 activation, platelets from Cdg1 low mice were markedly impaired in their ability
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CalDAG-GEFI Fcr2a-tg FcγRIIa transgenic mice to activate αIIbβ3 integrin ( Figure 3A , 3C, and 3E) and to aggregate when stimulated with various doses of Par4activating peptide ( Figure 4A and 4B), the collagen mimetic convulxin ( Figure 4C and 4D), or adenosine diphosphate ( Figure 4E and 4F). Cdg1 low platelets also showed a significant defect in α-granule release in response to activation with Par4-activating peptide ( Figure 3B ) or convulxin ( Figure 3D ). Importantly, however, integrin activation, granule release, and aggregation were significantly increased in Cdg1 low platelets when compared with platelets from Cdg1 −/− mice. Thus, expression of low levels of human CD-GEFI partially rescued integrin activation in platelets from mice lacking endogenous CD-GEFI. We next investigated whether this increase in integrin function translated to improved platelet adhesion to collagen under flow conditions. As expected, platelets in Cdg1 low blood exhibited markedly impaired adhesive function when compared with WT controls ( Figure 5 ). However, both platelet accumulation and platelet coverage of the collagen surface were significantly higher in Cdg1 low blood when compared with the Cdg1 −/− sample, both under low ( Figure 5A -5C) and high ( Figure 5D -5F) shear stress conditions. As shown in Figure 5C and 5F, Cdg1 low platelets only formed 3-dimensional thrombi when perfused over collagen at low shear conditions, confirming our previous observations that CD-GEFI is particularly important for platelet adhesion under arterial shear stress conditions. 12
Cdg1 low Mice Show Mild Defect in Hemostasis
A loss-of-function mutation or genetic knockout of Cdg1 leads to moderate to severe bleeding on challenge in humans 14 and mice, 4, 12 respectively. It is important to note, however, that unlike mice deficient in the integrin adapters talin-1 or kindlin-3, 15, 16 complete deficiency in CD-GEFI does not lead to perinatal bleeding and increased mortality. Consistent with these findings, Cdg1 low mice showed no signs of perinatal bleeding or reduced viability (not shown). To evaluate hemostasis, we subjected Cdg1 low mice to a model of precise laserinduced injury to the saphenous vein, 17 as well as the more widely used tail bleeding time assay. Injuries in the saphenous vein bleeding model are small (<100 μm in diameter) and, thus, can be imaged and analyzed by intravital microscopy for platelet adhesion (Figure 6A and 6B) and time to hemostatic plug formation ( Figure 6A and 6C) (also see Movies I-III in the online-only Data Supplement). Compared with WT controls, both platelet adhesion and hemostasis were markedly impaired in Cdg1 −/− mice. A significant reduction in platelet adhesion and a delay in hemostatic plug formation were also observed in Cdg1 low mice. However, although Cdg1 −/− mice bled for the entire observation period (300 s), hemostasis was achieved within ≈80 s in Cdg1 low mice. The delay in hemostatic plug formation observed in Cdg1 low mice correlated well with a delay in platelet adhesion at the site of laser injury. Consistent with the findings in this small injury hemostasis model, we also observed markedly decreased blood loss from severed tails of Cdg1 low mice when compared with Cdg1 −/− mice ( Figure 6D ). In fact, blood loss in Cdg1 low mice was not significantly higher than that in WT control mice, even though we observed continuous oozing of small amounts of blood from the transected tails of ≈60% of Cdg1 low mice ( Figure 6E ). Together, these studies suggest that expression of ≈10% of CD-GEFI in platelets is sufficient to maintain hemostasis in mice.
Cdg1 low Mice Are Strongly Protected From Experimental Thrombosis
Mice lacking CD-GEFI are strongly protected from arterial thrombosis and immune-mediated thrombocytopenia and thrombosis. 12, 13 Given their minor hemostatic defect, we were curious to see whether Cdg1 low mice were still protected from experimental thrombosis. Similar to Cdg1 −/− mice, Cdg1 low mice did not form occlusive thrombi in a model of FeCl 3induced injury to the carotid artery ( Figure 7A and 7B ). In this model, vascular occlusion is defined as a reduction of blood flow by >75% caused by the formation of a large thrombus. Because thrombus formation was not directly visualized in this model, we were not able to compare platelet adhesion to sites of FeCl 3 injury between WT, Cdg1 −/− , and Cdg1 low mice. We did, however, visualize platelet adhesion in the laser injury hemostasis model ( Figure 6A ; Movies I-III in the online-only Data Supplement). In WT mice, hemostatic plug formation was characterized by a first phase of rapid growth that was followed by pacification of the thrombus, that is, the shrinking of the thrombus down to a core region. The observed kinetics of platelet adhesion to sites of laser injury in WT mice are consistent with studies by Brass and colleagues, who demonstrated that thrombus pacification is because of the reversible binding of weakly activated platelets in the shell region of the thrombus. 18 Interestingly, thrombi in Cdg1 low mice were markedly smaller and did not seem to contain a shell region. Thus, it is likely that Cdg1 low mice formed small platelet thrombi at sites of FeCl 3 injury, but that these thrombi cannot grow big enough to impede the blood flow in this high shear stress environment. We also subjected Cdg1 low mice to a recently established model of immune-mediated thrombocytopenia and thrombosis. 13 In this model, platelet activation and pulmonary embolism is triggered via FcγRIIA, a receptor that is expressed on human but not murine platelets. To circumvent this limitation, these studies were performed with transgenic mice expressing human FcγRIIA. 19 FcγRIIa transgenic mice (Fcr2a-tg) and Cdg1 low Fcr2a-tg mice were injected with an antibody against glycoprotein IX (GPIX), a subunit of the platelet von Willebrand receptor complex. As shown recently, anti-GPIX antibody treatment of mice leads to platelet activation and pulmonary embolism in an FcγRIIA-dependent fashion. 13 Consistent with previous results, injection of anti-GPIX antibody into Fcr2a-tg mice led to a >80% decrease in the peripheral platelet count ( Figure 7C ) and the formation of large pulmonary emboli ( Figure 7D and 7E) . In contrast, the peripheral platelet count in Cdg1 low Fcr2a-tg mice injected with anti-GPIX antibody dropped by only ≈30%, and platelet accumulation in the lungs was dramatically decreased compared with Fcr2a-tg mice.
Discussion
Current strategies to prevent excessive platelet activation and arterial thrombosis include inhibitors of the main platelet integrin, αIIbβ3, and drugs targeting feedback signaling by adenosine diphosphate and TxA 2 (P2Y12 antagonists and aspirin; also known as dual antiplatelet therapy 20, 21 ). αIIbβ3 antagonists provide powerful protection from thrombosis but also markedly increase the patients' risk for pathological bleeding. In comparison, dual antiplatelet therapy provides weaker protection from thrombosis but is safer with regard to unwanted bleeding. To provide a significant improvement over existing therapies, the next generation of antiplatelet drugs should be as effective as αIIbβ3 inhibitors in preventing thrombosis, but with a safety (bleeding) profile similar or better than that of dual antiplatelet therapy.
Here we report that mice expressing small amounts of CD-GEFI are strongly protected from arterial and immune complex-mediated thrombosis. Importantly, as compared with Cdg1 −/− mice, this protection in Cdg1 low mice does not come at the expense of a deficient hemostatic response. Thus, small amounts of functional CD-GEFI are sufficient to preserve most of the hemostatic function of platelets, but not sufficient for the formation of pathological thrombi. This phenotype is similar to that of mice with impaired, but not abolished, expression/function of the integrin adapter proteins, TALIN-1 22 or KINDLIN-3. 23 In all cases, αIIbβ3-mediated platelet aggregation is delayed, allowing for the formation of small hemostatic plugs. If confirmed in humans, these findings would suggest TALIN-1, KINDLIN-3, and CD-GEFI as promising new targets for antiplatelet therapy. Compared with TALIN and KINDLIN, however, CD-GEFI may be a preferred target because (1) its expression is largely confined to platelets and neutrophils, and (2) mice deficient in talin-1 15 or kindlin-3 16 but not Cdg1 −/− mice exhibit spontaneous bleeding and high perinatal mortality. Interestingly, impaired platelet function and bleeding on challenge are the main phenotypes of dogs 24 and humans 14, 25 lacking functional CD-GEFI, suggesting that neutrophil function is less dependent on the CD-GEFI/ RAP1 signaling pathway. Our work in Cdg1 −/− mice identified significant defects in neutrophil integrin activation and adhesion, 26 but these defects were mild when compared with those observed in knockout platelets or those in neutrophils lacking kindlin-3. 27 As neutrophils are known modulators of experimental thrombosis, 28 however, studies in mice lacking CD-GEFI in platelets or neutrophils only will be required to determine whether impaired neutrophil function contributes to the antithrombotic phenotype observed in CD-GEFI mutant mice. Based on our studies, we propose that targeting CD-GEFI could provide certain advantages over existing antiplatelet therapies. While P2Y12 inhibitors affect the sustained activation of RAP1 and, thus, protect from thrombosis by destabilizing existing thrombi, 12 lack of functional CD-GEFI delays platelet activation and impairs thrombus formation in mice 4, 12, 29 and humans. 14, 25 CD-GEFI also plays a critical role for ITAMdependent platelet activation, 29 and both knockout 12, 13, 30 and Cdg1 low mice are strongly protected from arterial and immune complex-mediated thrombosis. Thus, inhibitors of CD-GEFI are expected to provide significantly better protection from thrombosis than drugs targeting P2Y12. Obviously, CD-GEFI inhibitors would have to be carefully monitored in patients because complete lack of function in this protein is associated with a marked bleeding risk in humans and mice. 8, 9, 12, 14, 25 Alternatively, smarter strategies to inhibit CD-GEFI function could be developed. For example, our recent work demonstrated that deletion of the C1 regulatory domain in CD-GEFI leads to an ≈70% reduction in GEF activity. 12 If we succeed in identifying how the C1 domain contributes to CD-GEFI function, inhibitors could be developed that specifically target this regulatory domain. Such inhibitors would not need to be titrated in patients because complete inhibition of CD-GEFI could not be achieved with such an approach. Finally, inhibitors to CD-GEFI could be used as a safer alternative to αIIbβ3 inhibitors currently used in high-risk patients. The studies reported here combined with our previous work suggest that the antithrombotic effect of a putative CD-GEFI inhibitor would be comparable to that of αIIbβ3 inhibitors-but at a lower risk for bleeding.
In summary, we provide evidence that low-level expression of CD-GEFI leads to protection from thrombosis, but not to marked bleeding, in mice. Based on these findings, we propose that specific targeting of CD-GEFI would provide a significant improvement over clinically used antiplatelet therapies, such as αIIbβ3 inhibitors and dual antiplatelet therapy.
